Inhibition of Allergen-Induced Eosinophil Migration by Lipoxin (LX)A4and Aspirin-Triggered 15-Epi-LXA4
Eosinophils are clearly participants in allergic diseases and have effector roles in promoting the pathogenesis of these diseases. Indeed, the number of eosinophils and its secretory products are elevated in allergic inflamed tissues and have been shown to positively correlate with the severity of the disease.1-3Thus, new therapies for allergic disorders could be aided by the development of anti-eosinophilic tools. The most potent agents currently used for controlling severe eosinophilic reactions, including asthma, are the glucocorticoids4. However, the adverse effects of long term treatment with glucocorticoids have stimulated efforts to identify effective anti-inflammatory substitutes.
KeywordsPleural Fluid Pleural Cavity Inhibit Tumor Necrosis Factor Allergic Challenge Human Eosinophil
Unable to display preview. Download preview PDF.
- 3.M.E. Rothenberg. Eosinophilia.N. Engl. J. Med.28:1592 (1998).Google Scholar
- 6.C.N. Serhan, T. Takano, and J.F. Maddox. Aspirin-triggered 15-epi-lipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation. Receptors and pathways.In Lipoxygenases and Their Metabolites. Nigam and Pace-Asciak, editors. Plenum press, New York. p. 133 (1999).CrossRefGoogle Scholar
- 7.T.H. Lee, A.E. Crea, V. Gant, B.W. Spur, B.E. Marron, K.C. Nicolaou, E. Reardon, M. Brezinski, and C.N. Serhan. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases.Am. Rev. Respir. Dis.141:1453 (1990).PubMedCrossRefGoogle Scholar
- 18.C. Bandeira-Melo, M.F. Serra, B.L. Diaz, R.S.B. Cordeiro, P.M.R. Silva, H.L. Lenzi, Y.S. Bakhle, C.N. Serhan and M.A. Martins. COX-2-derived prostaglandin E2 and Lipoxin A, accelerate resolution of edema in Angistrongilus costaricensis-infected rats: relationship with concurrent eosinophilia.J. Immunol.164: 1029 (2000).PubMedGoogle Scholar
- 19.T. Takano, S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan. Aspirin-triggered 15-epilipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.J. Exp. Med.185:1693 (1997).PubMedCentralPubMedCrossRefGoogle Scholar
- 20.M.J. Sanz, P.D. Ponath, C.R. Mackay, W. Newman, M. Miyasaka, T. Tamatani, B.F. Flanagan, R.R. Lobb, T.J. Williams, S. Nourshargh, and P.J. Jose. Human eotaxin induces alpha 4 and beta 2 integrin-dependent eosinophil accumulation in rat skin in vivo: delayed generation of eotaxin in response to IL-4. J. Immunol. 160:3569 (1998).PubMedGoogle Scholar
- 22.K. Gronert, A. Gewirtz, J.L. Madara, and C.N. Serhan. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J. Exp. Med. 187:1285 (1998).PubMedCentralPubMedCrossRefGoogle Scholar